Evaluation of the effect of cannabidiol administration with and without nonsteroidal anti-inflammatory drugs in dogs with mobility disorders: a prospective, double-blind, crossover, placebo-controlled study DOI Creative Commons

Bryce Talsma,

Lindsay Elam, Stephanie McGrath

et al.

Frontiers in Veterinary Science, Journal Year: 2024, Volume and Issue: 11

Published: Sept. 25, 2024

Introduction With rapidly growing interest in the use of cannabidiol (CBD) management pain and other conditions, more information is needed on safety efficacy this supplement, particularly its co-administration with commonly used pharmaceuticals such as non-steroidal anti-inflammatory drugs (NSAIDs). This study sought to assess effect CBD dogs mobility impairments, well evaluate clinical tolerance together NSAIDs. Materials methods Forty-two client-owned diagnosed impairments were enrolled prospective, double-blind, crossover, placebo-controlled study. Baseline data collected for 10–14 days followed by random allocation either placebo or oil 45 a 30-day washout period between. was dosed at 5 mg/kg orally every 12 h masked administered equal volume. Outcome measures included objective gait analysis, accelerometry, metrology instruments. plasma levels serum biochemistry also along hepatic ultrasound if warranted. Results Thirty-eight finished thirty-nine least partial analysis. Compared baseline, receiving showed evidence improved outcomes based blinded veterinary assessments accelerometer data. placebo, some CBPI, CSOM, assessments, but not outcome measures. There increased ALP when co-administered NSAIDs compared administration alone. Additionally, there ALT elevations NSAID co-administration, elevation did show an increase over Discussion These results suggest potential therapeutic benefit greater seen While sample size that received further work-up liver enzyme small, chosen diagnostics varied, biopsies performed, appear be clinically apparent damage. Further research better understand larger population patient medications long term.

Language: Английский

Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs DOI Creative Commons
Alana C. Costa, Arquimedes Gasparotto,

Alana Anne Kaneda Garcia

et al.

Toxicology Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101918 - 101918

Published: Jan. 1, 2025

Language: Английский

Citations

0
Pharmacokinetics of cannabidiol, (-)-trans-Δ9-tetrahydrocannabinol, and their oxidative metabolites after intravenous and oral administration of a cannabidiol-dominant full-spectrum hemp product to beagle dogs DOI Creative Commons
Susanna E. Kitts-Morgan, Richard A. Sams,

William W. Muir

et al.

Frontiers in Veterinary Science, Journal Year: 2025, Volume and Issue: 12

Published: April 8, 2025

This study investigated the pharmacokinetics, safety, and tolerability of a full-spectrum CBD-dominant oil formulated in medium-chain triglycerides (MCT oil) after single intravenous (IV) administration, oral (PO) multiple administrations CBD at dose 2.2 mg/kg adult male female beagle dogs. The extract was administered to adult, intact dogs (male n = 4, 2) once intravenously, orally, every 12 h orally for 21 days mg CBD/kg body weight (BW). Blood samples were collected predetermined times measure concentrations serum CBD, 7-hydroxy-CBD (7-OH-CBD), 7-nor-7-carboxy-CBD (7-COOH-CBD), Δ9-tetrahydrocannabinol (Δ9-THC), 11-hydroxy-THC (11-OH-THC), 11-carboxy-THC (11-COOH-THC). Serum Δ9-THC analyzed estimate various pharmacokinetic parameters. Selected physical, behavioral, hematologic, blood chemical measurements obtained before during repeated administrations. Pharmacokinetics IV administration indicated median (range) systemic clearance (CL) 7.06 (6.14-10.5) mL/min/kg, steady-state volume distribution (Vss) 2.13 (1.10-2.85) L/kg, half-life 291 (183-508) min. extent availability 31.2 (17.7-35.7)%. characterized by CL 8.85 (6.88-14.4) Vss 1.98 (1.30-2.30) 169 (139-476) PO 40.9 (20.5-46.2)%. test article well tolerated all study. Although alkaline phosphatase increased study, they remained within normal limits. Both rapidly cleared exhibited extensive volumes distribution. Comparison hepatic flow estimated extraction ratio first pass metabolism which confirmed analyzing data. AUC0-∞ 7-OH-CBD compared not different, suggesting complete absorption from formulation MCT when with canned dog food.

Language: Английский

Citations

0
Tolerability of 2 and 4 mg/kg Dosing Every 12 Hour of a Cannabidiol- and Cannabidiolic Acid-Rich Hemp Extract on Mixed-Breed Dogs Utilized for Teaching in a Closed Colony DOI Creative Commons

Trista Mills,

Stephanie L. Myers, Daniel T. Hughes

et al.

Animals, Journal Year: 2024, Volume and Issue: 14(13), P. 1863 - 1863

Published: June 24, 2024

With the increase in popularity of utilizing cannabidiol (CBD) for human ailments, owners are actively interested possible utilization cannabinoid products their pets. The evaluation CBD-rich hemp as an anti-anxiolytic, anti-inflammatory, immunomodulator, and anti-epileptic supplement has been assessed previous studies dogs, with adverse events such ataxia or lethargy noted. In this study, was at two concentrations to ascertain impact on behavior well tolerability medication given a typically recommended dose then twice that dose. Eighteen dogs were utilized randomized, double-blinded, placebo-controlled, 3 × designed study. Each group six provided placebo, 2 mg/kg, 4 mg/kg cannabidiol/cannabidiolic acid (CBD/CBDA)-rich two-week intervals one-week washout periods between each treatment period. Throughout 10-week period, student evaluations performed, simulating clients’ subjective assessments. Improvements anxiety-related related not observed may indicate behavioral changes require higher dosing mitigate unwanted behaviors normal, healthy dogs. Furthermore, serum chemistry cortisol evaluated after period showing only mildly significant alkaline phosphatase when every 12 h, which is consistent previously reported CBD these concentrations. Adverse associated CBD/CBDA-rich extract h weeks reported, suggesting using young, safe during treatment.

Language: Английский

Citations

2
Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review DOI Creative Commons
Alessandra Di Salvo, Elisabetta Chiaradia, Monica Sforna

et al.

Veterinary Research Communications, Journal Year: 2024, Volume and Issue: 48(5), P. 2915 - 2941

Published: Aug. 20, 2024

Since the discovery of endocannabinoid system and due to empirical evidence therapeutic effects on several illnesses both in humans animals that follow administration exogenous cannabinoids (i.e., phytocannabinoids), numerous studies have been conducted. These investigations aimed identify expression distribution cannabinoid receptors healthy pathologic organs tissues different animal species define interactions phytocannabinoids with these receptors. In last decade, pharmacokinetics, efficacy tolerability many Cannabis derivatives formulations, mainly containing cannabidiol, main veterinary interest, also investigated. This manuscript summarizes findings reported by scientific published so far molecular mode action phytocannabinoids, localization tissues, as well dogs, cats, horses other interest. A deep knowledge issues is crucial for use purposes species.

Language: Английский

Citations

2
Evaluation of the effect of cannabidiol administration with and without nonsteroidal anti-inflammatory drugs in dogs with mobility disorders: a prospective, double-blind, crossover, placebo-controlled study DOI Creative Commons

Bryce Talsma,

Lindsay Elam, Stephanie McGrath

et al.

Frontiers in Veterinary Science, Journal Year: 2024, Volume and Issue: 11

Published: Sept. 25, 2024

Introduction With rapidly growing interest in the use of cannabidiol (CBD) management pain and other conditions, more information is needed on safety efficacy this supplement, particularly its co-administration with commonly used pharmaceuticals such as non-steroidal anti-inflammatory drugs (NSAIDs). This study sought to assess effect CBD dogs mobility impairments, well evaluate clinical tolerance together NSAIDs. Materials methods Forty-two client-owned diagnosed impairments were enrolled prospective, double-blind, crossover, placebo-controlled study. Baseline data collected for 10–14 days followed by random allocation either placebo or oil 45 a 30-day washout period between. was dosed at 5 mg/kg orally every 12 h masked administered equal volume. Outcome measures included objective gait analysis, accelerometry, metrology instruments. plasma levels serum biochemistry also along hepatic ultrasound if warranted. Results Thirty-eight finished thirty-nine least partial analysis. Compared baseline, receiving showed evidence improved outcomes based blinded veterinary assessments accelerometer data. placebo, some CBPI, CSOM, assessments, but not outcome measures. There increased ALP when co-administered NSAIDs compared administration alone. Additionally, there ALT elevations NSAID co-administration, elevation did show an increase over Discussion These results suggest potential therapeutic benefit greater seen While sample size that received further work-up liver enzyme small, chosen diagnostics varied, biopsies performed, appear be clinically apparent damage. Further research better understand larger population patient medications long term.

Language: Английский

Citations

0